# CJC-1295 Ipamorelin Dosage: What the Research Doses Were (No Advice)

> CJC-1295 Ipamorelin dosage, reviewed as research context only: the doses, routes, and half-lives studied in the literature — third person, study-attributed, with no human dosing advice.

What was administered, to which species, by which route, and for how long — reported as study facts, never as instructions.

## Read this first

This page reviews **CJC-1295 Ipamorelin dosage** as it appears in the research literature — and only there. It lists what was given to animals and, for CJC-1295, to healthy human volunteers in early pharmacology studies: the amounts, the injection routes, and how long each peptide lasts in the body. It does **not** tell anyone what to take. There is no validated human protocol for this fixed blend, no approved dose for either peptide, and self-administration falls entirely outside any studied research design. Every figure below is written in the third person and attributed to a study. Read it to understand how the compounds were *investigated*, not to plan a protocol.

## Cjc 1295 ipamorelin dosage: what was administered in studies

For **CJC-1295 (with DAC)**, human Phase 1 pharmacokinetic studies administered 30 to 90 µg/kg subcutaneously; the defining study used 30 or 60 µg/kg in ascending single and multiple doses in healthy adults [1]. GHRH-knockout mouse work used roughly 2 µg/day. For **CJC-1295 no-DAC (Mod GRF 1-29)**, there is no formal standalone human pharmacokinetic study; it appears in research protocols as a short pulsatile GHRH signal. For **ipamorelin**, dosing comes almost entirely from animal models: about 100 µg/kg three times daily and 0.5 mg/kg/day in bone studies, 0.01–1 mg/kg intravenously in gastrointestinal-motility work, with a roughly 1 µg/kg plateau of the GH response in rodent models [2]. No validated human pharmacokinetic dose for ipamorelin has been published. None of these figures is a recommendation; they are the values researchers used.

## Half-life: the most important number to get right

The two halves of this pair live in the body for wildly different lengths of time, which is the single most consequential fact for understanding any protocol. **CJC-1295 with DAC** has a half-life of roughly 6–8 days in humans because it is bound to albumin; in rats the peptide is detectable in plasma beyond 72 hours [1][5]. **CJC-1295 no-DAC (Mod GRF 1-29)** lasts on the order of minutes to about 30 minutes, like native GHRH(1-29), because the enzyme DPP-IV (dipeptidyl peptidase-IV) cleaves it quickly. **Ipamorelin** clears in under about two hours in rodent plasma, with the peak GH response around 40 minutes after dosing; no validated human half-life has been published. So a single "CJC-1295" label can mean a multi-day drug or a half-hour one — see the [cjc 1295 dac](/cjc-1295-dac) page for why that distinction changes everything.

## Routes and handling studied

The routes that appear in the literature are subcutaneous and intravenous injection, continuous subcutaneous infusion via osmotic minipump in rodent models, and intranasal delivery in some rodent ipamorelin pharmacokinetic work. On handling: lyophilised (freeze-dried) peptide is stable frozen for extended periods. Once reconstituted — typically with bacteriostatic water, sterile water containing 0.9% benzyl alcohol as a preservative — aqueous peptide solutions are kept refrigerated at 2–8 °C and degrade over weeks through asparagine deamidation, and the degradation products can be markedly less potent. Agitation and repeated freeze-thaw are avoided. GHRH analogues are cleaved by DPP-IV in plasma; CJC-1295's amino-acid substitutions and DAC were engineered specifically to resist that. This is standard laboratory-handling context, not a preparation guide.

## Why the human clinical data thins out

CJC-1295 (DAC) reached Phase 2 under ConjuChem before development was discontinued — public reporting attributes the end of one Phase 2 program to an adverse event in a single subject that was characterized as unrelated to the established mechanism. The Phase 1 data in healthy adults characterized the pharmacokinetics and dose-response that this site cites [1]. Ipamorelin was investigated as well, including a postoperative-ileus program, but was not advanced to approval. Critically, there is **no peer-reviewed human pharmacology study of the pre-mixed CJC-1295/ipamorelin combination itself** — every combination dosing claim rests on each compound's individual literature plus the general GHRH-plus-GHRP synergy evidence [3]. That absence is why this page reports research doses and stops there.

---

A calibrated reading of the CJC-1295 and ipamorelin literature — the measured findings logged to source, the untested fixed blend kept honestly apart, and the empty long-term-safety line left openly unfilled; not a clinic, not a vendor, not a prescription.